Urology Times

09/06/2025

Kevin Koo, MD, MPH, recently sat down with Urology Times to discuss a study on the impact of a digital stone measurement tool on surgeon decision-making during ureteroscopy.

Kevin Koo, MD, MPH, discusses a recent study on the utility of a digital stone measurement tool for ureteroscopy.

09/05/2025

WATCH 🎥: Stephen J. Freedland, MD, discusses findings from a recent systematic review examining the relationship between diet and prostate cancer risk and outcomes.

Surprisingly, the Mediterranean diet—which has shown benefits in other areas of health—was not consistently linked to prostate cancer risk reduction.

09/05/2025

Updated data from cohort C of the BOND-003 trial show consistent efficacy and favorable tolerability with cretostimogene grenadenorepvec in patients with high-risk BCG-unresponsive NMIBC.

Learn more:

CG Oncology plans to initiate a BLA submission with the FDA in Q4 of 2025.

09/04/2025

Investigators at Johns Hopkins Medicine and collaborating institutions have developed a noninvasive urine test that shows strong promise in prostate cancer detection.

The biomarker panel demonstrated the ability to detect prostate cancer even in men with prostate-specific antigen levels in the normal range.

09/04/2025

The pivotal cohort in the phase 2 LEGEND trial, exploring detalimogene voraplasmid in high-risk NMIBC, has reached its enrollment goal.

The LEGEND trial is evaluating detalimogene voraplasmid in patients with high-risk non–muscle invasive bladder cancer.

09/03/2025

The enrollment goal has been met in the phase 3 PIVOT-006 trial, which is comparing RFS with cretostimogene grenadenorepvec vs surveillance following TURBT in patients with IR-NMIBC.

The trial is assessing RFS rates with cretostimogene grenadenorepvec vs surveillance following TURBT.

09/03/2025

The American Cancer Society has released its annual Prostate Cancer Statistics report, showing increasing incidence rates alongside slowing declines in mortality.

The report showed rising incidence rates and a slowing of mortality declines in addition to persistent racial disparities.

09/02/2025

Predicine has begun the FDA premarket approval process for its urine cfDNA NGS assay, PredicineCARE, as a companion diagnostic in bladder cancer.

Predicine has submitted the first module of a PMA application for their urine cfDNA NGS assay PredicineCARE.

09/02/2025

Hong Truong, MD, highlights key findings from a study evaluating the utilization of genetic counseling and testing in patients with kidney cancer.

Hong Truong, MD, MS, highlights key findings on genetic counseling rates in patients with kidney cancer.

09/01/2025

Take a look back through last month's FDA decisions in urology in our latest regulatory recap!

A recap of the FDA submissions and regulatory decisions in urology from August 2025.

09/01/2025

This Labor Day, we honor urologists, researchers, and healthcare staff who work tirelessly to improve patient lives 💙💧. Thank you for your dedication.

08/29/2025

Sandip Prasad, MD, outlines 3 key takeaways from the ENVISION trial, which supported the approval of mitomycin for intravesical solution in patients with LG-IR-NMIBC.

Sandip M. Prasad, MD, MPhil, outlines 3 key takeaways from the ENVISION trial, which evaluated mitomycin for intravesical solution in patients with LG-IR-NMIBC.